Litcius/Paper detail

Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

Ryan Thaliffdeen, Anthony Yu, Karen L. Rascati

2024Clinical Drug Investigation11 citationsDOI

Topics & Concepts

MedicineMigrainePerspective (graphical)PharmacotherapyCalcitonin gene-related peptideIntensive care medicineMigraine treatmentAlternative medicinePharmacologyPsychotherapistPsychiatryPsychologyInternal medicineComputer scienceArtificial intelligencePathologyNeuropeptideReceptorMigraine and Headache StudiesTraumatic Brain Injury ResearchNicotinic Acetylcholine Receptors Study
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model | Litcius